Screener
Moderna MRNA Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $145M+2.1% | $389M+260% | $678M-29.8% | $1.02B-45.4% | $142M-41.1% | ||
| $93M-21.8% | $955M+961% | $452M-38.8% | $207M-59.7% | $119M+3.5% | ||
| $52M+126% | -$566M-3,244% | $226M-0.4% | $809M-40.0% | $23M-81.7% | ||
| 35.9%+19.7pp | -145.5%-162pp | 33.3%+9.8pp | 79.6%+7.2pp | 16.2%-36.1pp | ||
| $651M-7.0% | $649M-24.2% | $775M-30.9% | $801M-29.6% | $700M-42.7% | ||
| $216M-6.1% | $173M-18.4% | $308M-12.3% | $268M-4.6% | $230M-14.2% | ||
| —— | $1.78B+53.5% | $1.54B-30.6% | $1.28B-34.0% | $1.05B-34.6% | ||
| -$815M+10.1% | -$1.39B-32.2% | -$857M+31.2% | -$260M-271% | -$907M+33.5% | ||
| -562.1%+76.7pp | -356.8%+615pp | -126.4%+2.6pp | -25.6%-21.8pp | -638.7%-73.2pp | ||
| -$19M-338% | -$18M-350% | -$12M+58.6% | $0+100% | $8M+130% | ||
| -$767M+6.2% | -$1.33B-38.4% | -$799M+32.5% | -$187M-990% | -$818M+36.0% | ||
| $15M+114% | $9M+28.6% | $27M+142% | $13M+62.5% | $7M— | ||
| -$782M+5.2% | -$1.34B-38.3% | -$826M+26.3% | -$200M-1,638% | -$825M+35.5% | ||
| -539.3%+41.7pp | -345.2%+554pp | -121.8%-5.9pp | -19.7%-20.4pp | -581%-50.3pp | ||
| -$1.97+7.5% | -$3.40-34.9% | -$2.11+27.5% | -$0.51-1,800% | -$2.13+36.0% | ||
| -$815M+10.1% | -$1.39B-32.2% | -$857M+31.2% | -$260M-271% | -$907M+33.5% |
FAQ
- What is Moderna's revenue?
- Moderna (MRNA) generated $2.2B in revenue over the trailing twelve months, down 27.6% year over year.
- Is Moderna profitable?
- Moderna is not currently profitable: it reported a net loss of $3.2B over the trailing twelve months, a -141.4% net margin.
- What are Moderna's profit margins?
- Gross margin is 23.4% and operating margin is -149.0%, with a -141.4% net margin.
- What is Moderna's earnings per share?
- Moderna's diluted EPS over the trailing twelve months is $-7.99.
- Where does Moderna's income statement data come from?
- Every line is extracted from Moderna's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
